Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)

References

• Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012;69(7):856–867.
   PubMedGoogle Scholar
• Haass C, Selkoe DJ. Serum Amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Cell. 1993;75:1039–1042.
   PubMed Web of Science ®Google Scholar
• Valotassiou V, Malamitsi J, Papatriantafyllou J, et al. SPECT and PET imaging in Alzheimer’s disease. Ann Nucl Med. 2018;32(9):583‐593.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643‐663.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis. 2018;62(3):1125‐1140.
   Web of Science ®Google Scholar
• Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345‐347.
   PubMed Web of Science ®Google Scholar
• Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science. 2009;323(5920):1473‐1477.
   PubMed Web of Science ®Google Scholar
• Zhou L, Brouwers N, Benilova I, et al. Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β’-site Increases Aβ generation. EMBO Mol Med. 2011;3(5):291‐302.
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96‐99.(••)
   PubMed Web of Science ®Google Scholar
• Howard R, Liu KY. Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol. 2020;16(2):63‐64.
   PubMed Web of Science ®Google Scholar
• Kumalo HM, Soliman ME. A comparative molecular dynamics study on BACE1 and BACE2 flap flexibility. J Recept Signal Transduct Res. 2016;36(5):505‐514.
   PubMed Web of Science ®Google Scholar
• Henderson JA, Harris RC, Tsai CC, et al. How Ligand protonation state controls water in protein-ligand binding. J Phys Chem Lett. 2018;9(18):5440‐5444.
   Web of Science ®Google Scholar
• Malamas MS, Barnes K, Johnson M, et al. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem. 2010;18(2):630‐639.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-D] [1,3] thiazine-2-amine compounds as inhibitors of APP, BACE1 and BACE2. WO2013164730. 2013.
   Google Scholar
• Dineen TA, Chen K, Cheng AC, et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5ʹH-spiro[chromeno[2,3-b]pyridine-5,4ʹ-oxazol]-2ʹ-amine (AMG-8718). J Med Chem. 2014;57(23):9811‐9831.(••)
   Web of Science ®Google Scholar
• Low JD, Bartberger MD, Chen K, et al. Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D. Med Chem Commun. 2017;8(6):1196‐1206.
   Google Scholar
• Hilpert H, Guba W, Woltering TJ, et al. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease. J Med Chem. 2013;56(10):3980–3995.(•)
   PubMed Web of Science ®Google Scholar
• Pettus LH, Bourbeau MP, Bradley J, et al. Discovery of AM-6494: A potent and orally efficacious β-site Amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with in vivo selectivity over BACE2. J Med Chem. 2020;63(5):2263–2281.(•)
   PubMed Web of Science ®Google Scholar
• Huang Y, Strobel ED, Ho CY, et al. Macrocyclic BACE inhibitors: optimization of a micromolar hit to nanomolar leads. Bioorg Med Chem Lett. 2010;20(10):3158–3160.
   PubMed Web of Science ®Google Scholar
• Zuhl AM, Nolan CE, Brodney MA, et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nat Commun. 2016;7:13042.(•)
   PubMed Web of Science ®Google Scholar
• Zhu K, Xiang X, Filser S, et al. Beta-site Amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6. Biol Psychiatry. 2018;83(5):428‐437(•).
   Web of Science ®Google Scholar
• Mirsafian H, Mat Ripen A, Merican AF, et al. Amino acid sequence and structural comparison of BACE1 and BACE2 using evolutionary trace method. Sci World J. 2014;2014:482463.
   Google Scholar
• Esterhazy D, Stuetzer I, Wang H, et al. Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass. Cell Metab. 2011;14:365–377.
   PubMed Web of Science ®Google Scholar
• Rochin L, Hurbain I, Serneels L, et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A. 2013;110:10658–10663.
   PubMed Web of Science ®Google Scholar
• Shimshek DR, Jacobson LH, Kolly C, et al. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. Sci Rep. 2016;6:21917.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen K, Sloan SA, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex [published correction appears in. J Neurosci. 2015 Jan 14;35(2): 846–6.] J Neurosci. 2014;34(36):11929–11947.
   Web of Science ®Google Scholar
• (a) Eli Lilly and company. [cited 2020 Oct 13]. https://www.lilly.com/discovery/pipeline; (b) ClinicalTrials.gov. [cited 2020 Oct 13]. https://clinicaltrials.gov/ct2/show/NCT02989389.
   Google Scholar
• Stützer I, Selevsek N, Esterházy D, et al. Systematic proteomic analysis identifies β-site amyloid precursor protein cleaving enzyme 2 and 1 (BACE2 and BACE1) substrates in pancreatic β-cells. J Biol Chem. 2013;288(15):10536‐10547.
   PubMed Web of Science ®Google Scholar
• Rulifson IC, Cao P, Miao L, et al. Identification of human Islet Amyloid polypeptide as a BACE2 Substrate. PLoS One. 2016;11(2):e0147254.
   PubMed Web of Science ®Google Scholar
• Voytyuk I, Mueller SA, Herber J, et al. BACE2 distribution in major brain cell types and identification of novel substrates. Life Sci Alliance. 2018;1(1):e201800026.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [cited https://clinicaltrials.gov/ct2/show/NCT03036280, accessed 2020 October 13.
   Google Scholar
• Alić I, Goh PA, Murray A, et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain. bioRxiv. 2020. DOI:10.1101/2020.01.29.918037.
   Google Scholar
• (a) Novartis international AG. [cited 2020 Oct 13]. Available from: https://www.novartis.com/news/media-releases/novartis-amgen-and-banner-alzheimers-institute-discontinue-clinical-program-bace-inhibitor-cnp520-alzheimers-prevention; (b) ClinicalTrials.gov. [cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03131453
   Google Scholar
• AstraZeneca plc. [ cited 2020 Oct 13]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html#
   Google Scholar
• Merck & Co. Inc. [cited 2020 Oct 13]. Available from: https://investors.merck.com/news/press-release-details/2018/Merck-Announces-Discontinuation-of-APECS-Study-Evaluating-Verubecestat-MK-8931-for-the-Treatment-of-People-with-Prodromal-Alzheimers-Disease/default.aspx
   Google Scholar
• Alzforum.org. [ cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/atabecestat
   Google Scholar
• Alzforum.org. [ cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/pf-06751979
   Google Scholar
• Alzforum.org. [ cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/ly3202626
   Google Scholar
• ClinicalTrials.gov. [ cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02989389
   Google Scholar
• Alzforum.org. [cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/ly2886721
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT00621010
   Google Scholar
• Sparve E, Quartino AL, Lüttgen M, et al. Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839. J Pharmacol Exp Ther. 2014;350(2):469‐478.
   PubMed Web of Science ®Google Scholar
• Alzforum.org. [cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/bi-1181181
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01462851
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01592331
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01482013
   Google Scholar
• Previous reviews on BACE1 inhibitors: (a) Probst G, Xu YZ. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opin Ther Pat. 2012;22(5):511–540; (b) Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014;24(9):2033‐2045; (c) Hall A, Gijsen HJM. Targeting β-Secretase (BACE) for the Treatment of Alzheimer’s Disease. Comprehensive Medicinal Chemistry III. 2017;7:326-383; (d) Prati F, Bottegoni G, Bolognesi ML, et al. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease. J Med Chem. 2018;61(3):619‐637; (e) Ghosh AK, Osswald HL. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev. 2014;43(19):6765‐6813.; (f) Yuan J, Venkatraman S, Zheng Y, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013;56(11):4156‐4180; (g) Hsiao CC, Rombouts F, Gijsen HJM. New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorg Med Chem Lett. 2019;29(6):761‐777.
   PubMed Web of Science ®Google Scholar
• Allergenesis biotherapeutics, Compounds and their use as BACE1 inhibitors. WO2016172255. 2016.
   Google Scholar
• Amgen Inc., Beta-Secretase modulators and methods of use. WO2007061930. 2007.
   Google Scholar
• Amgen Inc., Beta-Secretase modulators and methods of use. WO2007062007. 2007.
   Google Scholar
• Dineen TA, Weiss MM, Williamson T, et al. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012;55(21):9025‐9044.
   Web of Science ®Google Scholar
• Amgen Inc., Aminodihydrooxazine and aminodihydrothiazine spiro compounds as beta-secretase modulators and their preparation and medical use. WO2011115928. 2011.
   Google Scholar
• Amgen Inc., Spirotetracyclic ring compounds as beta-secretase modulators and their preparation and use in the treatment of diseases. WO2011115938. 2011.
   Google Scholar
• Amgen Inc., Preparation of pyridinylspirochromenopyridineiosindolamine derivatives and analogs for use as beta-secretase modulators. WO2012019056. 2012.
   Google Scholar
• Amgen Inc., Preparation of spiro-amino-imidazolone and spiro-amino-dihydropyrimidinone compounds as beta-secretase modulators for therapy. WO2012071279. 2012.
   Google Scholar
• Amgen Inc., Preparation of 5-amino-oxazepine and 5-amino-thiazepane compounds as β-secretase antagonists. WO2012109165. 2012.
   Google Scholar
• Amgen Inc., Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use. WO2012112462. 2012.
   Google Scholar
• Amgen Inc., Preparation of amino-oxazine and amino-dihydrothiazine compounds as β-secretase modulators. WO2013044092. 2013.
   Google Scholar
• Amgen Inc., Preparation of dihydrospirochromenopyridinethiazinediamine derivatives and analogs for use as beta-secretase modulators. WO2014078314. 2014.
   Google Scholar
• Huang H, La DS, Cheng AC, et al. Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2012;55(21):9156‐9169.
   Web of Science ®Google Scholar
• Epstein O, Bryan MC, Cheng AC, et al. Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2014;57(23):9796‐9810(•).
   Web of Science ®Google Scholar
• Fielden MR, Werner J, Jamison JA, et al. Retinal toxicity induced by a novel β-secretase inhibitor in the Sprague-Dawley rat. Toxicol Pathol. 2015;43(4):581‐592.
   PubMed Web of Science ®Google Scholar
• Low, JD, Bartberger, MD, Chen, K et al. MedChemComm 2017;8(6):1196–1206.
   Google Scholar
• Amgen Inc., Aminodihydrothiazine and aminodioxidodihydrothiazine compounds as beta-secretase antagonists and their preparation. WO2014059185. 2014.
   Google Scholar
• Schering Corporation. Preparation of 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors. WO2012139425. 2012.
   Google Scholar
• Hoffmann-La Roche FAG, Preparation of 5-amino-[1,4]thiazine derivatives useful as BACE1 inhibitors in the prevention and/or treatment of Alzheimer’s disease. WO2013174781. 2013.
   Google Scholar
• Amgen Inc., Bridged bicyclic aminothiazine dioxide compounds as inhibitors of beta-secretase and their preparation. WO2015017407. 2015.
   Google Scholar
• Amgen Inc., Preparation of vinylphenyl and vinylpyridinyl 1,4-thiazinamine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use. WO2018112094. 2018.
   Google Scholar
• Amgen Inc., Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use. WO2016022724. 2016.
   Google Scholar
• Amgen Inc., Preparation of cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use. WO2014138484. 2014.
   Google Scholar
• Low JD, Bartberger MD, Cheng Y, et al. Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation. Bioorg Med Chem Lett. 2018;28(6):1111–1115.
   PubMed Web of Science ®Google Scholar
• Tadano G, Komano K, Yoshida S, et al. Discovery of an extremely potent thiazine-based β-secretase inhibitor with reduced cardiovascular and liver toxicity at a low projected human dose. J Med Chem. 2019;62(20):9331–9337.
   PubMed Web of Science ®Google Scholar
• Amgen Inc., Cyclopropathiazin-2-amine compounds as beta-secretase inhibitors and their preparation. WO2016022724. 2016.
   Google Scholar
• Amgen Inc., Preparation of vinylphenyl thiazinamine compounds as beta-secretase inhibitors and methods of use. WO2018112083. 2018.
   Google Scholar
• Amgen Inc., Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use. WO2017024180. 2018.
   Google Scholar
• Amgen Inc., Oxazine derivatives as beta-secretase inhibitors and methods of use. WO2018112081. 2018.
   Google Scholar
• Comentis, Inc. and Astellas Pharma Inc., Oxadiazole compounds which inhibit beta-secretase activity, their synthesis, and therapeutic use for treating Alzheimer’s disease. WO2012054510. 2012.
   Google Scholar
• Astellas Pharma Inc. and Comentis, Inc., Chromane compounds as BACE inhibitors and their preparation. WO2013181202. 2013.
   Google Scholar
• Boehringer Ingelheim international GMBH and Vitae Pharmaceuticals Inc., Inhibitors of beta-secretase. WO2013134085. 2013.
   Google Scholar
• Boehringer Ingelheim international GMBH and Vitae Pharmaceuticals Inc., Inhibitors of beta-secretase. WO2014035860. 2014.
   Google Scholar
• Vitae Pharmaceuticals Inc. and Boehringer Ingelheim international GMBH, Inhibitors of beta-secretase. WO2010105179. 2010.
   Google Scholar
• Bristol-Myers Squibb Company, Tricyclic compounds as inhibitors for the production of beta-amyloid and their preparation. WO2012162330. 2012.
   Google Scholar
• Wu Y-J, Guernon J, Rajamani R, et al. Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. Bioorg Med Chem Lett. 2016;26(23):5729–5731.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company, Preparation of bicyclic thiazine Compounds for the reduction of beta-amyloid production. WO2012162334. 2012.
   Google Scholar
• Edwards PD, Albert JS, Sylvester M, et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem. 2007;50:5912–5925.(••)
   PubMed Web of Science ®Google Scholar
• Wu Y-J, Guernon J, Yang F, et al. Targeting the BACE1 active site flap leads to a potent inhibitor that elicits robust brain aβ reduction in rodents. ACS Med Chem Lett. 2016;7(3):271–276.
   PubMed Web of Science ®Google Scholar
• Buck institute for research on aging, Hydantoins that modulate BACE-mediated APP processing. WO2014127042. 2014.
   Google Scholar
• Nantneuro, LLC, Compositions for APP for BACE inhibition and uses therefore. WO2017035529. 2017.
   Google Scholar
• ClinicalTrials.gov. [cited 2020 Oct 13]. https://clinicaltrials.gov/ct2/show/NCT03036280
   Google Scholar
• Eisai R&D management co., LTD, Fused aminodihydrothiazine derivatives. WO2012093148. 2012.
   Google Scholar
• Eisai R&D management co., LTD, Fused aminodihydrothiazine derivatives. WO2012098461. 2012.
   Google Scholar
• Eisai R&D management co., LTD, Fused aminodihydrothiazine derivatives useful as BACE inhibitors. WO2012098213. 2012.
   Google Scholar
• Eisai R&D management co., LTD, Preparation of 4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3]thiazin-2-amine derivatives for the treatment of Alzheimer-type dementia. GB2512975. 2014.
   Google Scholar
• Eisai R&D management co., LTD, Fused Aminodihydro-Oxazine Derivatives. WO2011009897. 2011.
   Google Scholar
• Eisai R&D management co., LTD, Fused Aminodihydro-Oxazine Derivatives. WO2011009898. 2011.
   Google Scholar
• Eisai.com. [cited 2020 Oct 13]. https://www.eisai.com/ir/library/presentations/pdf/e4523_191030.pdf
   Google Scholar
• Elan pharmaceuticals Inc., Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof. WO2013142613. 2013.
   Google Scholar
• Janssen Pharmaceutica NV, 5,6-Dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE). WO 2011154431. 2011.
   Google Scholar
• Janssen Pharmaceutica NV, 5-(3-4-aminophenyl)-5-alkyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives. WO2013083556. 2013.
   Google Scholar
• Rombouts FJ, Tresadern G, Delgado O, et al. 1,4-Oxazine β-secretase 1 (BACE1) inhibitors: from hit generation to orally bioavailable brain penetrant leads. J Med Chem. 2015;58:8216–8235(•).
   PubMed Web of Science ®Google Scholar
• Gijsen HJM, Alonso de Diego SA, De Cleyn M, et al. Optimization of 1,4-oxazine β-secretase 1 (BACE1) inhibitors toward a clinical candidate [published correction appears in J Med Chem. 2018 Dec 27; 61(24):11415]. J Med Chem. 2018;61(12):5292–5303.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, 3-Amino-5,6-dihydro-1H-pyrazin-2-one derivatives useful for the treatment of Alzheimer’s disease and other forms of dementia. WO2012000933. 2012.
   Google Scholar
• Janssen Pharmaceutica NV, 5-amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful for the treatment of Alzheimer’s disease and other forms of dementia. WO2011154374. 2011.
   Google Scholar
• Tresadern G, Delgado F, Delgado O, et al. Rational design and synthesis of aminopiperazinones as β-secretase (BACE) inhibitors. Bioorg Med Chem Lett. 2011;21(24):7255–7260.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, 3,4-Dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE). WO2012120023. 2012.
   Google Scholar
• Janssen Pharmaceutica NV, 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE). WO2012038438. 2012.
   Google Scholar
• Janssen Pharmaceutica NV, 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE). WO2014198851. 2014.
   Google Scholar
• Janssen Pharmaceutica NV, 4-Amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE). WO2014198854. 2014.
   Google Scholar
• Janssen Pharmaceutica NV, 4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE). WO2014198853. 2014.
   Google Scholar
• Oehlrich D, Peschiulli A, Tresadern G, et al. Evaluation of a series of β-secretase 1 inhibitors containing novel heteroaryl-fused-piperazine amidine warheads. ACS Med Chem Lett. 2019;10(8):1159–1165.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, Inhibitors of beta secretase. WO2018162443. 2018.
   Google Scholar
• Janssen Pharmaceutica NV, Inhibitors of beta secretase. WO2018162444. 2018.
   Google Scholar
• Janssen Pharmaceutica NV, Inhibitors of beta secretase. WO2018162445. 2018.
   Google Scholar
• Woltering TJ, Wostl W, Hilpert H, et al. BACE1 inhibitors: a head group scan on a series of amides. Bioorg Med Chem Lett. 2013;23(14):4239–4243(•).
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, 2,3,4,5-tetrahydropyridin-6-amine derivatives. WO2017050978. 2017.
   Google Scholar
• Janssen Pharmaceutica NV, 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compounds. WO2018083247. 2018.
   Google Scholar
• Shionogi & Co., Ltd. and Janssen Pharmaceutica NV, Bicyclic heterocycle derivatives having selective bace1 inhibitory activity. WO2019208509. 2019.
   Google Scholar
• Peschiulli A, Oehlrich D, Rombouts F, et al. 3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: potent and permeable BACE-1 inhibitors. Bioorg Med Chem Lett. 2020;30(8):126999.
   PubMed Web of Science ®Google Scholar
• Mateu N, Ciordia M, Delgado O, et al. A versatile approach to CF3-containing 2-pyrrolidones by tandem Michael addition-cyclization: exemplification in the synthesis of amidine class BACE1 inhibitors. Chemistry. 2015;21(33):11719–11726.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors beta-secretase. WO2016096979. 2016.
   Google Scholar
• Alzdiscovery.org. [cited 2020 Oct 13]. https://www.alzdiscovery.org/news-room/announcements/alzheimers-drug-discovery-foundation-partners-with-shionogi-and-janssen.
   Google Scholar
• May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011;31(46):16507‐16516(•).
   Web of Science ®Google Scholar
• Eli Lilly and company, BACE inhibitors. WO2011005738. 2011.
   Google Scholar
• May PC, Willis BA, Lowe SL, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35(3):1199–1210.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and company. BACE inhibitors. WO2014204730. 2014.
   Google Scholar
• Mandal M, Wu Y, Misiaszek J, et al. Structure-based design of an iminoheterocyclic β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor that lowers central Aβ in nonhuman primates. J Med Chem. 2016;59(7):3231–3248(•).
   PubMed Web of Science ®Google Scholar
• Eli Lilly and company, Tetrahydropyrrolothiazine compounds. WO2013151832. 2013.
   Google Scholar
• Eli Lilly and company, BACE inhibitors. WO2014066132. 2014.
   Google Scholar
• Eli Lilly and company, Tetrahydropyrrolothiazine compounds. WO2014143579. 2014.
   Google Scholar
• Garcia-Losada P, DeBaillie AM, de Diego JE, et al. Synthesis, optimization, and large-scale preparation of the low-dose central nervous system-penetrant BACE1 inhibitor LY3202626 via a [3 + 2] nitrone cycloaddition. Org Process Res Dev. 2020;24(2):306–314.
   Web of Science ®Google Scholar
• Eli Lilly and company, Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor. WO2016043997. 2016.
   Google Scholar
• Alzforum.org. [cited 2020 Oct 13]. https://www.alzforum.org/news/conference-coverage/bump-road-or-disaster-bace-inhibitors-worsen-cognition
   Google Scholar
• Eli Lilly and company, Aminothiazine compounds. WO2015138208. 2015.
   Google Scholar
• Eli Lilly and company, Combination therapy of BACE-1 inhibitor and anti-N3PGLU abeta antibody. WO2018034977. 2018.
   Google Scholar
• Eli Lilly and company, Combination therapy. WO2018075339. 2018.
   Google Scholar
• Eli Lilly and company, N-[3-[2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-(trifluoromethyl)pyridine-2-carboxamide and its (4aR,5S,7aS) isomer as a selective BACE1 inhibitor for treating e.g. Alzheimer’s disease. WO2017200863. 2017.
   Google Scholar
• Eli Lilly and company, Aminothiazines and their use as BACE1 inhibitors. WO2018031334. 2018.
   Google Scholar
• Eli Lilly and company, Selective BACE1 inhibitors. WO2016149057. 2016.
   Google Scholar
• Eli Lilly and company, 1,4-oxazines useful as selective BACE1 inhibitors. WO2018039062. 2018.
   Google Scholar
• H. Lundbeck A/S, 2-aminothiazinylheteroaryls as BACE1 inhibitors for the treatment Alzheimer’s disease. WO2013182638. 2013.
   Google Scholar
• H. Lundbeck A/S, 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment Alzheimer’s disease. WO2015124576. 2015.
   Google Scholar
• H. Lundbeck A/S, 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment Alzheimer’s disease. WO2016075062. 2016.
   Google Scholar
• H. Lundbeck A/S, 2-amino-6-difluoromethyl-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment Alzheimer’s disease. WO2016075063. 2016.
   Google Scholar
• H. Lundbeck A/S, 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment Alzheimer’s disease. WO2016075064. 2016.
   Google Scholar
• H. Lundbeck A/S, 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors. WO2017025559. 2017.
   Google Scholar
• H. Lundbeck A/S, 6-amino-5-fluoro-5-(fluoromethyl)-2,3,4,5-tetrahydropyridin-2-yl-phenyl-5-(methoxy-D3)-pyrazine-2-carboxamides and fluorinated derivatives thereof as BACE1 inhibitors. WO2018114910. 2018.
   Google Scholar
• H. Lundbeck A/S, Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines. WO2017025532. 2017.
   Google Scholar
• H. Lundbeck A/S, 2-amino-7a-phenyl-3,4,4a-5,7,7a-hexahydrofuro[3,4-B]pyridines as BACE1 inhibitors. WO2017025565. 2017.
   Google Scholar
• Investor.lundbeck.com. [cited 2020 Oct 13]. https://investor.lundbeck.com/static-files/100bc1d0-679e-4953-8527-01536fa9727c
   Google Scholar
• Merck Sharp & Dohme corp., 2-spiro-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions and their use. WO2013028670. 2013.
   Google Scholar
• Merck Sharp & Dohme corp., C2-Azaspiro iminothiazine dioxides as BACE inhibitors. WO2014150344. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., C5-Spiroiminothiazine dioxides as BACE inhibitors, compositions, and their use. US20160222032. 2016.
   Google Scholar
• Merck Sharp & Dohme corp., C-6 azaspiro iminothiadiazine dioxides as BACE inhibitors. WO2014099768. 2015.
   Google Scholar
• Merck Sharp & Dohme corp., C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors, compositions, and their use. WO2015094930. 2015.
   Google Scholar
• Merck Sharp & Dohme corp., C-5 Spiro iminothiadiazine dioxides as BACE inhibitors. WO2014099788. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., C5, C6 oxacyclic-fused iminothiazine dioxide compounds BACE inhibitors. WO2014099794. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., C5, C6 oxacyclic-fused iminothiazine dioxide compounds BACE inhibitors and their use. WO2012138734. 2012.
   Google Scholar
• Merck Sharp & Dohme corp., C5-C6 fused tricyclic iminothiazine dioxide compounds as BACE inhibitors, compositions, and their use. WO2016053828. 2016.
   Google Scholar
• Merck Sharp & Dohme corp., C5-C6 carbocyclic fused iminothiazine dioxide compounds as BACE inhibitors, compositions, and their use. WO2017095759. 2017.
   Google Scholar
• Merck Sharp & Dohme corp., Iminothiazepane dioxide compounds as BACE inhibitors, compositions, and their use. WO2015095104. 2015.
   Google Scholar
• Merck Sharp & Dohme corp., S-imino-S-oxo iminothiazine compounds as BACE inhibitors, compositions, and their use. WO2014150331. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., S-imino-S-oxo iminothiazine compounds as BACE inhibitors, compositions, and their use. WO2014150340. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., BACE inhibitors of iminothiadiazine dioxides. WO2014093190. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use. WO2014062549. 2014.
   Google Scholar
• Merck Sharp & Dohme corp., Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use. WO2016118404. 2016.
   Google Scholar
• Merck Sharp & Dohme corp., C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use. WO2015187437. 2015.
   Google Scholar
• Merck Sharp & Dohme corp., C5-C6-oxacyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use. WO2017139210. 2017.
   Google Scholar
• Merck Sharp & Dohme corp., C5-C6-oxacyclic fused iminothiazine dioxides as BACE inhibitors, compositions, and their use. WO2017139209. 2017.
   Google Scholar
• Merck Sharp & Dohme corp., Diazine-fused amine compounds as BACE inhibitors, compositions and their use. WO2016044120. 2016.
   Google Scholar
• Novartis AG, Oxazine derivatives and their use in the treatment of neurological disorders. WO2012006953. 2012.
   Google Scholar
• Novartis AG, Crystalline oxazine derivative and its as BACE inhibitors. WO2012095451. 2012.
   Google Scholar
• Neumann U, Rueeger H, Machauer R, et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol Neurodegener. 2015;10:44.
   PubMed Web of Science ®Google Scholar
• Neumann U, Machauer R, Shimshek DR. The β-secretase (BACE) inhibitor NB-360 in preclinical models: from amyloid-β reduction to downstream disease-relevant effects. Br J Pharmacol. 2019;176(18):3435–3446.
   PubMed Web of Science ®Google Scholar
• Novartis AG, Novel heterocyclic derivatives and their use in the treatment of neurological disorders. WO2012095469. 2012.
   Google Scholar
• Neumann U, Ufer M, Jacobson LH, et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease. EMBO Mol Med. 2018;10(11):e9316(•).
   PubMed Web of Science ®Google Scholar
• Novartis AG, An oxazine derivative for use in the prevention of Alzheimer’s disease in at risk patients. WO2018015868. 2018.
   Google Scholar
• Novartis AG, BACE-2 inhibitors for the treatment of metabolic disorders. WO2012095521. 2012.
   Google Scholar
• Novartis AG, Novel oxazine derivatives and their use in the treatment of disease. WO2013054291. 2013.
   Google Scholar
• Novartis AG, 2-amino-4-(pyridin-2-yl)-5,6-dihydro-4H-1,3-oxazine derivatives and their use as BACE-1 and/or BACE-2 inhibitors. WO2013027188. 2013.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A., 2-amino-5,5-difluoro-5,6-dihydro-4H-oxazines as BACE1 and/or BACE2 inhibitors. WO2011069934. 2011.
   Google Scholar
• Alzforum.org. [cited 2020 Oct 13]. https://www.alzforum.org/news/conference-coverage/umibecestat-driven-cognitive-decline-reversible
   Google Scholar
• Pfizer Inc., Lactams as beta secretase inhibitors, WO2012172449. 2012.
   Google Scholar
• Bell J, O’Neill BT, Brodney M, et al. A Novel BACE inhibitor (PF-05297909): A two-part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta-amyloid in a first-in-human study. Poster abstract P1-351. Alzheimers Dement. 2013;9(4):Supplement 287.
   Google Scholar
• Pfizer Inc., Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds. WO2013030713. 2013.
   Google Scholar
• Pfizer Inc., Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds. WO2014045162. 2014.
   Google Scholar
• Pfizer Inc., Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds. WO2013164730. 2013.
   Google Scholar
• Pfizer Inc., Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds. US20140228356. 2014.
   Google Scholar
• Pfizer Inc., Carbocyclic- and heterocyclic-substituted hexhydropyrano [3,4-d][1,3]thiazin-2-amine compounds. WO2014097038. 2014.
   Google Scholar
• Butler CR, Brodney MA, Beck EM, et al. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. J Med Chem. 2015;58(6):2678–2702.
   PubMed Web of Science ®Google Scholar
• Brodney MA, Beck EM, Butler CR, et al. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem. 2015;58(7):3223–3252(••).
   PubMed Web of Science ®Google Scholar
• Pfizer Inc., Substituted phenyl hexahydropyano [3,4-d][1,3] thiazin-2-amine compounds. WO2014125397. 2014.
   Google Scholar
• Pfizer Inc., Hexahydropyano [3,4-d][1,3] thiazin-2-amine compounds as inhibitors of BACE1. WO2014091352. 2014.
   Google Scholar
• Butler CR, Ogilvie K, Martinez-Alsina L, et al. Aminomethyl-derived beta secretase (BACE1) inhibitors: engaging Gly230 without an anilide functionality. J Med Chem. 2017;60(1):386–402.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc., 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[2,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amide. WO2015155626. 2015.
   Google Scholar
• Pfizer Inc., N-[2-(-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[2,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amide. WO2017051276. 2017.
   Google Scholar
• Pfizer Inc., N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as BACE inhibitors. WO2017051294. 2017.
   Google Scholar
• Pfizer Inc., Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as BACE inhibitors. WO2017051303. 2017.
   Google Scholar
• O’Neill BT, Beck EM, Butler CR, et al. Design and synthesis of clinical candidate PF-06751979: a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking hypopigmentation. J Med Chem. 2018;61(10):4476–4504(•).
   PubMed Web of Science ®Google Scholar
• Qiu R, Ahn JE, Alexander R, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of PF-06751979, a potent and selective oral BACE1 inhibitor: results from phase I studies in healthy adults and healthy older subjects. J Alzheimers Dis. 2019;71(2):581–595(•).
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazine derivatives. WO2011020806. 2011.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,4 oxazines as BACE1 and/or BACE2 inhibitors. WO2012098064. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,4 oxazines as BACE1 and/or BACE2 inhibitors. WO2012104263. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds. WO2011138293. 2011.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,4 oxazepines as BACE1 and/or BACE2 inhibitors. WO2012126791. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,4 oxazepines as BACE1 and/or BACE2 inhibitors. WO2012110459. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,4 oxazepines as BACE1 and/or BACE2 inhibitors. WO2012136603. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., cyclopropyl-fused-1,3-thiazepines as BACE 1 and/or BACE 2 inhibitors. WO2013004676. 2013.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Amino oxazine derivatives. WO2011070029. 2011.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Fluoromethyl-5,6-dihydro-4H-[1,3]oxazines. WO2013110622. 2013.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Fluoro-[1,3]oxazines as BACE1 inhibitors. WO2014114532. 2014.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Halogen-alkyl-1,3-oxazines as BACE1 and/or BACE2 inhibitors. WO2012168164. 2012.
   Google Scholar
• Jacobsen H, Ozmen L, Caruso A, et al. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014;34(35):11621–11630(•).
   PubMed Web of Science ®Google Scholar
• Alzforum.org. [cited 2020 Oct 13]. Available from: https://www.alzforum.org/therapeutics/rg7129
   Google Scholar
• Hoffmann-La Roche Inc. and Siena biotech S.P.A., 1,3 oxazines as BACE1 and/or BACE2 inhibitors. WO2012139993. 2012.
   Google Scholar
• Hoffmann-La Roche Inc., [1,3]Oxazines. WO2012168175. 2012.
   Google Scholar
• Hoffmann-La Roche Inc. and Siena biotech S.P.A., BACE inhibitors. WO2014166906. 2014.
   Google Scholar
• F. Hoffmann-La Roche Inc., Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors. WO2012163790. 2012.
   Google Scholar
• Hoffmann-La Roche Inc., Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as BACE1 inhibitors. WO2014001228. 2014.
   Google Scholar
• F. Hoffmann-La Roche AG, N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors. WO2013041499. 2013.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors. WO2012107371. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,3-oxazines as BACE1 and/or BACE2 inhibitors. WO2012156284. 2012.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., 1,3-oxazines-2-amine derivatives acting as BACE inhibitors for the treatment of Alzheimer’s disease. WO2015132141. 2015.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Trifluormethyloxazine amidines as BACE1 inhibitors. WO2016012384. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG and Siena biotech S.P.A., Fluoro-[1,3]-oxazines as BACE1 inhibitors. WO2016001266. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG., BACE 1 inhibitors. WO2017148878. 2017.
   Google Scholar
• F. Hoffmann-La Roche AG., 2,2,2-Trifluoroethyl-thiadiazines. WO2016023927. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG., BACE1 inhibitors. WO2016150785. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG., BACE1 inhibitors. WO2017025491. 2017.
   Google Scholar
• F. Hoffmann-La Roche AG., BACE1 inhibitors. WO2016055496. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG., 5-Aryl-1-imino-1-oxo-[1,2,4]thiadiazines. WO2015091595. 2015.
   Google Scholar
• F. Hoffmann-La Roche AG., Pyridyl-triazabicycles. WO2016012422. 2016.
   Google Scholar
• F. Hoffmann-La Roche AG., BACE1 inhibitors. WO2016071211. 2016.
   Google Scholar
• Fuchino K, Mitsuoka Y, Masui M, et al. Rational design of Novel 1,3-Oxazine based β-Secretase (BACE1) inhibitors: incorporation of a double bond to reduce P-gp Efflux leading to robust Aβ reduction in the brain. J Med Chem. 2018;61(12):5122–5137(•).
   PubMed Web of Science ®Google Scholar
• Shionogi & Co., Ltd., Preparation of 2-aminodihydrothiazine derivatives as β-secretase inhibitors. WO2007049532. 2007.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of thiazole and thiazine derivatives as β-secretase inhibitors. WO2009151098. 2009.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of substituted 2-amino-4H-1,3-thiazine derivatives as β-secretase (BACE1) inhibitors. WO2011070781. 2011.
   Google Scholar
• Shionogi & Co., Ltd., Aminothiazine or aminooxazine derivative having amino linker for treatment of Alzheimer disease. WO2011058763. 2011.
   Google Scholar
• Shionogi & Co., Ltd. Preparation of pyridine derivatives as BACE-1 inhibitors. WO2012147762. 2012.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of oxazine derivatives as BACE-1 inhibitors. WO2012147763. 2012.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of 4-amino-1,3-thiazine or oxazine derivatives for treatment of diseases related to secretion and/or deposition of amyloid β proteins. WO2011077726. 2011.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of fused aminodihydropyrimidine derivatives as BACE1 inhibitors. WO2012057247. 2012.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of naphthyridine derivatives as BACE1 inhibitors. WO2012057248. 2012.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of dihydrooxazine and oxazepine derivatives having BACE1 inhibitory activity. WO2014065434. 2014.
   Google Scholar
• Shionogi & Co., Ltd., Preparation of dihydrothiazines and dihydrooxazine derivatives having BACE1 inhibitory activity. WO2015156421. 2015.
   Google Scholar
• Nakahara K, Fuchino K, Komano K, et al. Discovery of potent and centrally active 6-substituted 5-fluoro-1,3-dihydro-oxazine β-secretase (BACE1) inhibitors via active conformation stabilization. J Med Chem. 2018;61(13):5525–5546.
   PubMed Web of Science ®Google Scholar
• Shionogi & Co., Ltd., Dihydrothiazine derivatives as BACE1 inhibitors and their preparation. WO2017061534. 2017.
   Google Scholar
• Anan K, Iso Y, Oguma T, et al. Trifluoromethyl dihydrothiazine-based β-secretase (BACE1) inhibitors with robust central β-amyloid reduction and minimal covalent binding burden. ChemMedChem. 2019;14(22):1894–1910.
   PubMed Web of Science ®Google Scholar
• Shionogi & Co., Ltd., Preparation of tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity. WO2019208693. 2019.
   Google Scholar
• Fujimoto K, Matsuoka E, Asada N, et al. Structure-based design of selective β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: targeting the flap to gain selectivity over BACE2. J Med Chem. 2019;62(10):5080–5095(•).
   PubMed Web of Science ®Google Scholar
• Shionogi & Co., Ltd., Fused heterocyclic derivatives having selective BACE1 inhibitory activity. WO2020009179. 2020.
   Google Scholar
• High point pharmaceuticals LLC, Substituted iminodazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors. WO2011119465. 2011.
   Google Scholar
• Zhengzou Tetranov pharmaceutical co. Ltd., CN107892697. 2017.
   Google Scholar
• Zhengzou Tetranov pharmaceutical co. Ltd., US20190330236A1. 2019.
   Google Scholar
• Eisai R&D management co. Ltd., Novel fused aminodihydrothiazine derivative. WO2010038686. 2010.
   Google Scholar
• Hampel H, Vassar R, De Strooper B, et al. The β-secretase BACE1 in Alzheimer’s disease [published online ahead of print. Biol Psychiatry. [2020 Feb 13];S0006-3223(20):30063–30069(•).
   Google Scholar
• Fierce Biotech.com. https://www.fiercebiotech.com/biotech/lilly-s-latest-bace-setback-embodies-obstacles-alzheimer-s-r-d
   Google Scholar
• Panza F, Lozupone M, Watling M, et al. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother. 2019;19(7):599–602.
   PubMed Web of Science ®Google Scholar